| PPD Opens Pharmacovigilance and Medical Communications Center in Sofia, Bulgaria (Business Wire) WILMINGTON, N.C.----PPD, Inc. today announced the opening of a pharmacovigilance and medical communications center in Sofia, Bulgaria, delivering its full range of drug safety, medical information and medical writing services to meet growing client demand. us.rd.yahoo.com |
Summer of Sensitivity - Video Crest® Pro-Health™ Sensitive Shield™ Toothpaste Teams Up with Alison Sweeney and Feeding America to Kick-off the Summer of Sensitivity feedproxy.google.com |
Is Mannkind the Next Takeover Target? KLLJ Investments submits: It is no secret that Big Pharma is in desperate need to fill their pipeline to replace the unprecedented number of BlockBuster drugs set to come off patent in the coming years. Sanofi-Aventis (SNY) is a top 5 Pharma company that has openly stated they will be looking to do small to mid-size acquisitions (>$15B) to beef up their pipeline. Rumors abound on who the targets are. Analysts point to Allergan (AGN,) Biogen (BIIB) and Genzyme (GENZ) as likely candidates. What if that target is a relatively unknown company on the verge of releasing the next blockbuster? What if that target is MannKind Corporation (MNKD)? It seems outrageous that a company with a market cap under $800M could warrant a premium of more than 100% or so. However, MannKind isn’t your normal public company. Al Mann, founder and CEO of MannKind still owns 44.5% of the outstanding shares of MannKind. Al has previously stated that he won’t invest in a venture unless he can make at minimum 10X his investment. So far, Al Mann has invested $800M+ out of his own pocket to fund MannKind. The company has spent north of $1.6B to develop their Technosphere platform and to bring AFREZZA to market. No acquisition of MannKind will happen without Al Mann’s approval and that number would be $10B or more in my estimation. To learn more about Technosphere and AFREZZA, you can read my previous articles and blogs on the subject. Complete Story » seekingalpha.com |
Genzyme Sees End to Drug's Rationing Genzyme expects to stop rationing its rare-disease treatment Fabrazyme during the first half of next year, ending a shortage that began in 2009. online.wsj.com |
Novartis in Pact to Speed Up Vaccine Production Novartis said it entered a partnership with newly formed Synthetic Genomic Vaccines to use new technologies aimed at speeding up production of seasonal and pandemic flu vaccines. online.wsj.com |